TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06101797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote supervised exercise group
Description: The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised by video call. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person supervised exercise group
Description: The exercise protocol for this group consists of individualized muscle-strengthening exercises for the lower extremities supervised at a physiotherapy clinic. The intervention will occur 2-3 times per week, each lasting approximately 40 minutes. The exercise protocol will consist of six muscle-strengthening exercises for the lower extremities, which will be guided, alternating muscle groups. In the first two weeks of treatment, exercise intensity will be monitored for participants to complete two sets of 8-12 repetitions in dynamic exercises. From the third week onward, participants will progress to one additional set. Adjustments to weight-bearing, the external load imposed by the elastic band, and exercise position throughout the protocol will be performed to maintain the participant's level of effort. After supervised exercise treatment, patients will be encouraged to maintain an exercise routine with the same exercise protocol, however, without physiotherapy supervision.
Study: NCT04968080

Intervention type: DEVICE
Intervention: Infrared Cameras Inc. (ICI) FMX 400 Infrared (IR) Camera System
Description: Infrared thermal camera

Intervention type: DEVICE
Intervention: Welch Allyn SureTemp Plus 690
Description: Oral thermometer

Intervention type: DEVICE
Intervention: Welch Allyn ThermoScan PRO 6000
Description: Ear thermometer

Intervention type: DEVICE
Intervention: Infrared Cameras Inc. (ICI) HotSpot Infrared (IR) NonContact Infrared Thermometer
Description: Forehead temperature gun
Study: NCT06363994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orelabrutinib
Description: Eligible patients will receive Orelabrutinib orally as per the protocol，until disease progression or other reasons for treatment discontinuation，whichever comes first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Injection
Description: Eligible patients will receive Bendamustine by injection as per the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine Injection
Description: Eligible patients will receive Bendamustine by injection as per the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Eligible patients will receive Rituximab by injection as per the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Eligible patients will receive Rituximab by injection as per the protocol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orelabrutinib Placebo
Description: Eligible patients will receive Orelabrutinib Placebo orally as per the protocol
Study: NCT05966441

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: The safety of curcumin has been widely demonstrated, and curcumin has a variety of potential pharmaceutical applications. Curcumin exhibits antioxidant, anti-inflammatory and anticancer properties and has been described as neuroprotective against neurological disorders.~Many of curcumin's pharmacological benefits arise from its antioxidant or anti-inflammatory properties. Curcumin appears to have significant potential for treatment of diseases that result from oxidative stress.~Curcumin is provided in soft gelatin capsules each capsule contains 1 g of curcumin and patient is asked to take 2 capsules daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (PTX), the most widely used anticancer drug, is applied for the treatment of various types of malignant diseases. Mechanisms of PTX action represent several ways in which PTX affects cellular processes resulting in programmed cell death. PTX is frequently used as the first-line treatment drug in breast cancer Paclitaxel dose in adjuvant therapy after doxorubicin and cyclophosphamide every 3 weeks 175mg/m2 IV or Weekly 80 mg/m2 IV..~Paclitaxel dose in neoadjuvant therapy every 3 weeks 175 mg/m2 IV.
Study: NCT04631601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acapatamab
Description: Acapatamab will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Abiraterone will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: AMG 404 will be administered as an intravenous (IV) infusion.
Study: NCT06569199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Bracing
Description: Premade fabricated braces in three sizes (small, medium and large) that have been designed for the pediatric age group between 0-5 years old will be stocked at the Alberta Children's Hospital. Braces will be applied to participants in the emergency department. As these braces are designed to allow for positional adjustments, if deemed necessary adjustments will be made by the attending orthopaedic surgeon at subsequent follow-up visit(s).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Spica Cast
Description: The current standard of care for diaphyseal pediatric hip fractures in children aged 6 months to 5 years old is hip spica casting. A hip spica is a hard cast that covers a child's body from the chest down to their knees or ankles allowing for fracture immobilization to promote healing. Application of the spica cast occurs in the operating room and requires a general anaesthetic. Caring for a child in a hip spica cast presents significant challenges for caregivers due to the cast's cumbersome size and restricted mobility which makes routine caregiver activities like daily hygiene, toileting, transportation and skin surveillance difficult. Inadequate maintenance of the spica cast may result in skin complications, necessitating extra visits for cast adjustments, or potentially requiring revision casting in the operating room.
Study: NCT05709574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 MG
Description: Tadalafil 20 mg tablets will be taken daily for 2 weeks alone and then for 8 weeks in combination with neoadjuvant chemotherapy in the window between gastric/GEJ adenocarcinoma diagnosis and interventional surgery.
Study: NCT06041724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with recombinant human endostatin and first-line chemotherapy
Description: Envafolimab: 300mg day1, s.c. Q3W; Recombinant human endostatin: 210mg day1, Intravenous pump for 72 hours, Q3W; Temozolomide: 150 mg/m2 d1-5, i.v. Q3W; Cisplatin: 25 mg/m2 d1-3, i.v. Q3W.~All of the above drugs were used for 6 cycles, and then Envafolimab and recombinant human endostatin continued only in patients with no progression in the first stage until disease progression as defined by RECIST1.1, unacceptable toxicity, withdrawal from the study or death, or no more than 2 years.
Study: NCT04997174

Intervention type: DRUG
Intervention: Celecoxib
Description: Patients in ERAS group received celecoxib
Study: NCT05785780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted CRC Screening Toolkit
Description: Strategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
Study: NCT05430490

Intervention type: PROCEDURE
Intervention: MRI
Description: Multimodal neuroimaging on 3T Prisma Fit MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: Multimodal neuroimaging on 3T Prisma Fit MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: Multimodal neuroimaging on 3T Prisma Fit MRI

Intervention type: PROCEDURE
Intervention: MRI
Description: Multimodal neuroimaging on 3T Prisma Fit MRI

Intervention type: OTHER
Intervention: NeuroPsychological Testing
Description: A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.

Intervention type: OTHER
Intervention: NeuroPsychological Testing
Description: A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.

Intervention type: OTHER
Intervention: NeuroPsychological Testing
Description: A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.

Intervention type: OTHER
Intervention: NeuroPsychological Testing
Description: A series of written, verbal, and motor tasks requiring the participant to follow instructions, remember words and numbers, draw objects, and complete timed actions.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Laboratory reports (CMP, CBC, Lipids)

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Laboratory reports (CMP, CBC, Lipids)

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Laboratory reports (CMP, CBC, Lipids)

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Laboratory reports (CMP, CBC, Lipids)

Intervention type: OTHER
Intervention: Questionnaires
Description: Life history, current behaviors, and substance use surveys

Intervention type: OTHER
Intervention: Questionnaires
Description: Life history, current behaviors, and substance use surveys

Intervention type: OTHER
Intervention: Questionnaires
Description: Life history, current behaviors, and substance use surveys

Intervention type: OTHER
Intervention: Questionnaires
Description: Life history, current behaviors, and substance use surveys

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
Study: NCT05689346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone power therapy
Description: high tone power therapy
Study: NCT05430490

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back

Intervention type: PROCEDURE
Intervention: Lumbar Puncture
Description: Optional procedure which involves obtaining cerebral spinal fluid through a needle in the lower back
Study: NCT05689346

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy exercises
Description: traditional physical therapy exercises for improving balance
Study: NCT05500885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF device, Quantum Tx, Singapore
Description: The options of the appliance will be adjusted to 1.5mT, 10Hz on the diseased leg for 10 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard rehabilitation and sham PEMF therapy for CAI
Description: Balance training and muscle strengthening
Study: NCT04986345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)-4
Description: 4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)-4
Description: 4 intervals of 4 minutes at 90% of maximum cardiac frequency, interspersed with 3-minute rests at 70% of maximum cardiac frequency. The session will last 32 minutes, including warm-up and cooldown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)-10
Description: 10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)-10
Description: 10 intervals of 1 minutes at 90% of maximum cardiac frequency, interspersed with 1-minute rests at 70% of maximum cardiac frequency. The session will last 34 minutes, including warm-up and cooldown.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Participants are to stay seated for 30 minutes while reading or watching television.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rest
Description: Participants are to stay seated for 30 minutes while reading or watching television.
Study: NCT05860192

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Use of this virtual reality headset to deliver a single mindfulness session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application for mindfulness
Description: Application used to realize mindfulness in virtual reality
Study: NCT06302556

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune checkpoints analysis
Description: The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune checkpoints analysis
Description: The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immune checkpoints analysis
Description: The researcher will analyze immune checkpoint molecules, which will include the lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), V-domain Ig suppressor of T cell activation (VISTA), besides the canonical PD1 and ligands L1 and L2, T cell immunoglobulin and ITIM domain (TIGIT) and CTLA-4. In addition, Foxp3, GATA3 and TOX will be analyzed as specific lineage markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Gene expression analysis
Description: Immune cells will be purified from bronchoalveolar lavage; total RNA will be purified and subjected to gene expression analysis by Quantigene multiplex 80-plex Assay, which allows to evaluate simultaneously the follow mRNA targets: CCL2, CCL3, CCL5, CXCL10, CSF2, CSF3, IL1A, IL1B, IL1RN, IL6, IL6R, IL8, IL10, IL12B, IL17A, IL18, IL22, IL28A, TNF, TNFRSF4, IFNA2, IFNB1, IFNG, IFI16, IFITM1, IFITM3, MX1, TLR3, TLR4, TLR7, TLR8, NOD1, NOD2, CASP1, NLRP3, PYCARD, CD44, CLEC4M, CD209, ITGA4, ITGB7, CH25H, ABCA1, HMGCS1, NR1H3, ACAT1, PDCD1, PTGS2, CD274, CD69, MPO, HAVCR2, TAP1, ERAP1, ERAP2, AGTR2, AGTR1, PPARG, CRP, IL7, IL12A, ACE2, ELOVL6, CD38, NOS2
Study: NCT05893940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Intensity Vibration Therapy
Description: Undergo LIMS vibration therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Intensity Vibration Therapy
Description: Undergo LIMS vibration therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05668416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: The training includes brochures and oral training prepared by the researchers in line with the literature and the training given in the hospital. Education brochure (Day surgery training brochure); An educational brochure was prepared by the researchers in line with the literature and practices in the institution. The brochure was composed of 3 sections: pre-operative, on the day of the operation and after the operation.
Study: NCT05434156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101
Description: ELE-101 solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELE-101 Placebo
Description: ELE-101 placebo matching solution for intravenous infusion
Study: NCT06067906

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric diet
Description: Hypocaloric diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dissociated diet
Description: Dissociated diet
Study: NCT05017675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fructose diet
Description: 4 week high fructose diet.~Intended composition (En%):~Carbohydrates: 60-70 Fat: 20-30 Protein: 10-15 Fructose: 20 SFA: 5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat diet
Description: 4 week high saturated fat diet.~Intended composition (En%):~Carbohydrates: 35-45 Fat: 40-50 Protein: 10-15 Fructose: 5 SFA: 20
Study: NCT06577688

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement using a standard cuff device and a smartphone

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: Blood pressure measurement using a standard cuff device and a smartphone